EDG-15400 50 mg for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Aug 2026: Trial started, NCT07795814
  2. 31 Aug 2026: Trial registered, NCT07795814

The trials

NCT07795814: A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

State
Under way
Phase
Phase 2
People
90 planned
Started
25 Aug 2026
Primary completion
Dec 2027
Arms
EDG-15400 50 mg
Results
None posted
  1. 25 Aug 2026: Trial started
  2. 31 Aug 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.